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Introduction

1
Metal compounds have been applied in cancer therapy since 1965, 2 when Rosenberg discovered the cytotoxic activity of cis-Pt(NH 3 ) 2 Cl 2 3 (cisplatin) [1, 2] . Despite being used for over 30 years since their 4 successful introduction in the clinic, major problems concerned with 5 the side-effects and intrinsic or acquired resistance still remain [3, 4, 5] .
6
The mechanisms underlying resistance to cisplatin may be connected 7
with reduced intracellular accumulation due to reduced drug uptake 8 enhanced efflux, conjugation with intracellular thiols
9
(metallothionein, glutathione), enhanced repair of platinum DNA 10 adducts or changes in molecular pathways involved in regulation of 11 cell survival/cell death [6, 7] . Based on the limitations in the use of the 12 platinum drugs, novel anticancer metal compounds have been
13
designed with the aim of reducing side-effects or synthesizing drugs
14
with less propensity to induce drug resistance [8] . Early structure-importantly, some of these complexes have been found to retain 23 considerable efficacy against tumor cells resistant to cisplatin
24
[11, 12, 13, 14, 15] . Over recent years, alternative approaches were also 
30
In addition, their antioxidant, anti-inflammatory, antimicrobial and 31 antiviral activities have aroused great interest as candidates for the 32 synthesis of flavonoid synthetic derivatives [16, 17] . 
11
cisplatin was used as a reference compound.
12
Results and discussion 13
General observations
14
The novel platinum compound was synthesized according to the 15 Scheme 1. and subsequently characterized by elemental analysis,
16
ESI-MS, IR and NMR spectroscopy; X-ray analysis of the structure 17 was also performed. The anticancer activity was studied using 
22
Crystal Structure Description
23
The main aim of the X-ray crystallographic studies was to determine 
35
Atomic displacement ellipsoids are drawn at a 50% probability level. 
46
In the crystal lattice, two nitrogen N(3) atoms of the 3-aminoflavone Table 1 .
53
The length of the Pt-N bond, 2.064(5) Å, is significantly longer than 54 for the other complexes with the same ligand, which are about 
28
bond distance of 1.231(7) Å is in line with a double bond [33] .
29
The crystal-packing arrangement is mainly directed by hydrogen 
61
TCAP was found to be slightly less cytotoxic to the tested cancer 62 cell line than cisplatin. Furthermore, TCAP was also less toxic for 
67
For TCAP no significant differences were observed between L1210
68
and EJ cells and their cisplatin-resistant sublines: L1210R and
69
EJcisR. Hence, TCAP has the ability to retain cytotoxic activity
70
against cisplatin-resistant cell lines, which could be explained as S1 ).
7
Free 3-aminoflavone was not cytotoxic at concentration up to 100 8 µM [35] . These results are very promising, as they indicate that TCAP 9 has beneficial features for potential anticancer agents.
10
Apoptosis evaluation
11
Apoptotic pathways are important targets that should be considered 
13
shown are representative data of at least three individual studies. 
18
shown are representative data of at least three individual studies.
19
under the same conditions, with no more than 10% being detectable 
27
As the minimum time needed to induce apoptosis was found to be 4 
48
The assays showed that the studied compound induced apoptosis of apoptosis. This assay confirmed that the apoptosis process is 53 continues despite removal of the drug (Fig.7 and Fig.8 ).
54
Apoptotic DNA fragmentation
55
To check whether DNA degradation may be a result of the apoptosis 
12
18
38
condensation, and blebbing of the plasma membranes (see Fig. S2 ).
39
The results after 4 h of incubation and 20 h postincubation in fresh 40 medium are shown in Fig. 10 and 11.
41
Our results reveal that trans-Pt(3-af) 2 Cl 2 induce apoptosis more 
47
This experiment shows that the proapoptotic activity of compound 2
48
is 2-to 4-times higher than that of cisplatin. Therefore, our findings 
19
Synthesis of 3-aminoflavone (3-af)
20
The synthesis followed the procedure described elsewhere [28] .
21
Synthesis and characterization of trans-Pt(3-af) 2 Cl 2 
Synthesis of trans-Pt(3-af)
35
The structure of Pt(3-af)Cl 2 was determined by elemental analysis,
36
IR and FAB-MS spectroscopy but further X-ray experiment is still 37 required.
38
The atoms were located on a difference Fourier map. In the last step of 8 the refinement all the hydrogen atoms were constrained to ride on 9 their parent atoms using a rigid body model with isotropic 10 displacement parameters equal to 1.2 U eq of appropriate N or C 11 atom. A summary of crystallographic data is given in Table 1 . The 12 molecular geometry was calculated by PARST [39] and Platon [40] .
13
Selected bond distances and angles are summarized in Table 2. 14 Mercury version 2.4 [41] was used to present the intermolecular 15 interaction network.
16 Table 2 . Crystal data and structure refinement details 
Crystal Data
38
Centrifugation was carried out in a density gradient using 
67
Annexin-V/PI propidium iodide assay
69
The apoptotic cells were identified by flow cytometry using the 
14
Conclusions
15
The anticancer activity and molecular mechanisms of action of 
